Compare Rush Street Interactive Inc (RSI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rush Street Interactive Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Rush Street Interactive Inc trades at $18.31 (market cap $2.20B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 3.4× Rush Street Interactive Inc's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Rush Street Interactive Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rush Street Interactive Inc for 13 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| RSI | SYRE | |
|---|---|---|
Market Cap | $2.20B | $7.52B |
Volume | 4,146,093 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.52 | $108.92 |
52-Week Low | $15.89 | $22.18 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $1.87B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RSI trades at $19.07, up 1.92% with bearish technical signals but strong analyst support. The company shows revenue growth to $1.13B in 2025 with improving cash flow, though net margins remain thin at 2.33%. Recent Q2 2026 earnings beat expectations at $0.15 EPS, while institutional interest grows with BlackRock's $448M investment in August 2026.
Outlook remains positive with 77% analyst buy ratings and $33.75 price target offering 77% upside. Key risks include competitive pressures in online gaming and margin compression. The stock presents growth potential but requires monitoring of profitability trends and market sentiment shifts.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
